drugset / Trial / NCT04825496
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1
Unknown
18 enrolled
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
The First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of ssCART-19 in the treatment of patients with CD19 positive relapsed or refractory acute lymphoblastic leukemia.
Timeline
- Start
- 2021-04-09
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ssCART-19 Cells | Unknown | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |